Insight Molecular Diagnostics (IMDX) Accounts Payables (2015 - 2026)

Insight Molecular Diagnostics has disclosed Accounts Payables across 12 years of filings, most recently posting $1.6 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.6 million, down 29.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 29.14% YoY), and the FY2025 annual result was $2.5 million, up 508.61% from the prior year.
• Accounts Payables came in at $1.6 million for Q1 2026 at Insight Molecular Diagnostics, down from $2.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.6 million in Q2 2022 to a low of $379000.0 in Q2 2024.
• The 5-year median for Accounts Payables is $1.3 million (2022), against an average of $1.7 million.
• Across the five-year window, Accounts Payables sank 82.74% in 2024 and surged 508.61% in 2025, its largest moves.
• Insight Molecular Diagnostics' Accounts Payables stood at $1.3 million in 2022, then decreased by 23.94% to $953000.0 in 2023, then tumbled by 56.14% to $418000.0 in 2024, then soared by 508.61% to $2.5 million in 2025, then sank by 36.52% to $1.6 million in 2026.
• The last three Accounts Payables figures came in at $1.6 million (Q1 2026), $2.5 million (Q4 2025), and $602000.0 (Q3 2025), per Business Quant data.